Holocene Advisors LP Buys 38,880 Shares of Enovis Co. (NYSE:ENOV)

Holocene Advisors LP lifted its holdings in shares of Enovis Co. (NYSE:ENOV - Free Report) by 120.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 71,112 shares of the company's stock after purchasing an additional 38,880 shares during the period. Holocene Advisors LP owned 0.13% of Enovis worth $3,061,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Centiva Capital LP acquired a new stake in Enovis in the third quarter worth $326,000. Benjamin Edwards Inc. grew its stake in shares of Enovis by 34.9% in the 3rd quarter. Benjamin Edwards Inc. now owns 15,595 shares of the company's stock valued at $671,000 after buying an additional 4,035 shares during the period. Paloma Partners Management Co increased its position in Enovis by 121.6% in the 3rd quarter. Paloma Partners Management Co now owns 17,543 shares of the company's stock valued at $755,000 after buying an additional 9,626 shares in the last quarter. Hantz Financial Services Inc. raised its stake in Enovis by 18.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 224,396 shares of the company's stock worth $9,660,000 after buying an additional 35,294 shares during the period. Finally, FORA Capital LLC bought a new position in Enovis in the third quarter worth approximately $650,000. Institutional investors and hedge funds own 98.45% of the company's stock.

Enovis Stock Down 0.5 %

Shares of ENOV stock traded down $0.25 on Friday, hitting $47.63. The stock had a trading volume of 576,995 shares, compared to its average volume of 582,099. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.12. The business has a 50 day moving average of $43.62 and a 200 day moving average of $44.81. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of -21.86 and a beta of 1.94.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.62 by $0.11. The firm had revenue of $505.22 million for the quarter, compared to analysts' expectations of $504.44 million. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The company's quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.56 EPS. As a group, analysts expect that Enovis Co. will post 2.79 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ENOV shares. JPMorgan Chase & Co. lowered their target price on Enovis from $53.00 to $50.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. JMP Securities initiated coverage on shares of Enovis in a report on Thursday, October 3rd. They set an "outperform" rating and a $62.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and set a $65.00 price objective on shares of Enovis in a report on Thursday, November 7th. Finally, Evercore ISI lowered their target price on shares of Enovis from $62.00 to $58.00 and set an "outperform" rating on the stock in a report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Enovis presently has an average rating of "Moderate Buy" and a consensus price target of $67.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.